Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Peeva E, Yamaguchi Y, King B, Han G, Cox L, Banerjee A, Picardo M, Bae JM, Sloan A, Sinclair R, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active non-segmental vitiligo across Fitzpatrick skin types: results from a Phase 2b, randomized, dose-ranging study with an extension period

View Presentation
Oral Presentation
Yamaguchi Y, Peeva E, Shore R, Han G, Cox LA, Banerjee A, Thaci D, Hamzavi I, Sloan A, Ganesan AK, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active non-segmental vitiligo: results from a Phase 2b, randomized, placebo-controlled, dose-ranging study

View Presentation
Oral Presentation
Pourang A, Kohli I, Ezekwe N, Parks-Miller A, Mohammad T, Huggins R, Lim H, Deal LS, Lukic T, Zhang F, Hamzavi I September 10, 2022 EADV 2022 Vitiligo

Assessing the Reliability of Vitiligo Area Scoring Index with Digital Images of Vitiligo

View Presentation
Poster
Anderson P, Piercy J, Marwaha S, Lukic T, Lejeune A, Neary MP September 10, 2022 EADV 2022 Vitiligo

Real-World Treatment Patterns and Clinical Outcomes for Patients with Non-Segmental Vitiligo in the United States and Europe

View Presentation
Oral Presentation
Ferguson J, Eleftheriadou V, Nesnas J September 10, 2022 EADV 2022 Vitiligo

Vitiligo is associated with a reduction in incidence of melanoma and non-melanoma skin cancer: UK population-based cohort study

View Presentation